GRTX Galera Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GRTX

Price (delayed)

$0.1425

Market cap

$7.75M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.89

Enterprise value

-$15.39M

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera's lead ...

Highlights
The company's EPS rose by 20% YoY and by 13% QoQ
The company's debt fell by 2.6% QoQ
The quick ratio is down by 39% year-on-year and by 21% since the previous quarter
GRTX's equity is down by 30% YoY and by 10% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://galeratx.com
Peers: OMGA

Key stats

What are the main financial stats of GRTX
Market
Shares outstanding
54.39M
Market cap
$7.75M
Enterprise value
-$15.39M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$55.72M
EBITDA
-$55.65M
Free cash flow
-$48.93M
Per share
EPS
-$1.89
Free cash flow per share
-$1.08
Book value per share
-$2.88
Revenue per share
$0
TBVPS
$0.76
Balance sheet
Total assets
$37.78M
Total liabilities
$164.33M
Debt
$1.29M
Equity
-$126.55M
Working capital
$18.62M
Liquidity
Debt to equity
-0.01
Current ratio
2.47
Quick ratio
2.25
Net debt/EBITDA
0.42
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-146.9%
Return on equity
N/A
Return on invested capital
-462.7%
Return on capital employed
-221.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GRTX stock price

How has the Galera Therapeutics stock price performed over time
Intraday
3.11%
1 week
4.78%
1 month
-32.53%
1 year
-91.36%
YTD
-90.44%
QTD
-18.62%

Financial performance

How have Galera Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$57.24M
Net income
-$69.68M
Gross margin
N/A
Net margin
N/A
GRTX's net income is down by 11% YoY
The operating income has declined by 9% year-on-year

Growth

What is Galera Therapeutics's growth rate over time

Valuation

What is Galera Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 20% YoY and by 13% QoQ
GRTX's equity is down by 30% YoY and by 10% QoQ

Efficiency

How efficient is Galera Therapeutics business performance
The return on assets has dropped by 56% year-on-year and by 5% since the previous quarter
The ROIC has dropped by 51% since the previous quarter

Dividends

What is GRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GRTX.

Financial health

How did Galera Therapeutics financials performed over time
GRTX's total assets is 77% smaller than its total liabilities
The quick ratio is down by 39% year-on-year and by 21% since the previous quarter
The company's current ratio fell by 36% YoY and by 20% QoQ
The company's debt is 101% higher than its equity
GRTX's equity is down by 30% YoY and by 10% QoQ
The company's debt fell by 2.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.